Keyphrases
Israel
79%
Carbapenem-resistant Acinetobacter Baumannii
79%
Colistin
63%
Bloodstream Infection
47%
COVID-19
29%
Multidrug-resistant Gram-negative Bacteria
28%
Escherichia Coli
26%
Randomized Controlled Trial
25%
Severe Infection
23%
Israeli
22%
Meropenem
22%
Acinetobacter Baumannii (A. baumannii)
21%
Colorectal Surgery
21%
Combination Therapy
20%
Antimicrobial Resistance
18%
Healthcare Workers
18%
Carbapenem Resistance
17%
Bacteremia
17%
Clinical Failure
16%
Monotherapy
16%
Carbapenemase-producing Enterobacterales
15%
Confidence Interval
15%
Carbapenem-resistant Gram-negative Infections
15%
Murine Model
15%
Carbapenemases
15%
Population-based Study
14%
Hospital-onset
14%
National Cohort Study
14%
Surgical Site Infection
14%
Human Adenovirus Type 55
13%
Human Infection
13%
ESBL-PE
13%
In Vivo Fitness
13%
Ertapenem
13%
Enterobacterales
13%
Clinical Outcomes
12%
Sentinel
12%
Colistin-resistant
12%
14-day Mortality
12%
Carbapenem-resistant Enterobacterales
12%
Intensive Care Unit
11%
Colistin-meropenem
11%
Blood Culture
11%
Non-associated
10%
1-year Mortality
10%
Acute Hospital
10%
Antimicrobial Stewardship
10%
Carbapenemase
10%
Acinetobacter Infections
10%
Antibiotic Resistance
9%
Pharmacology, Toxicology and Pharmaceutical Science
Carbapenem
100%
Colistimethate
70%
Bloodstream Infection
68%
Infection
64%
Acinetobacter Baumannii
49%
Meropenem
31%
Gram Negative Bacterium
26%
Escherichia coli
26%
Infectious Agent
24%
Randomized Controlled Trial
23%
Carbapenemase
22%
Combination Therapy
18%
Diseases
17%
Antimicrobial Resistance
17%
Gram Negative Infection
16%
Monotherapy
15%
Antiinfective Agent
15%
Surgical Infection
14%
Prospective Study
13%
Ertapenem
13%
Asthma
13%
Extended Spectrum Beta Lactamase
12%
Antibiotics
12%
Acinetobacter Infection
10%
Randomized Clinical Trial
9%
Inflammation
9%
Klebsiella pneumoniae
8%
Metronidazole
8%
Enterobacteriaceae
8%
Biological Marker
8%
Penicillinase
8%
Pharmacokinetics
7%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
7%
Bacterial Infection
7%
Cohort Study
7%
Antibiotic Therapy
7%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
6%
Synergism
6%
Prevalence
6%
Meningitis
6%
Prospective Cohort Study
6%
Avibactam Plus Ceftazidime
6%
Case-Control Study
6%
Placebo
6%
Syndrome
6%
Therapeutic Drug Monitoring
6%
Beta Lactamase Inhibitor
6%
Third Generation Cephalosporin
6%
Chronic Bronchitis
6%
Subretinal Fluid
6%
Medicine and Dentistry
Carbapenem
80%
Infection
57%
Acinetobacter Baumannii
47%
Colistimethate
35%
Bloodstream Infection
30%
Gram-Negative Bacteria
26%
Randomized Controlled Trial
22%
Colorectal Surgery
21%
COVID-19
20%
Meropenem
18%
Pathogen
16%
Surgical Infection
15%
Carbapenemase
15%
Antiinfective Agent
15%
Escherichia coli
14%
Antibiotic Resistance
14%
Prospective Study
13%
Ertapenem
13%
Adenoviridae
13%
Extended Spectrum Beta Lactamase
12%
Antibiotics
12%
Combination Therapy
11%
Antibiotic Therapy
10%
Beta-Lactamase
10%
Gram-Negative Bacterial Infection
9%
Acinetobacter Infection
9%
Randomized Clinical Trial
9%
Metronidazole
8%
Biological Marker
8%
Health Care Cost
8%
Klebsiella pneumoniae
8%
Monotherapy
8%
Penicillinase
7%
Diseases
7%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
7%
Bacterial Infection
7%
Antibiotic Prophylaxis
7%
Therapeutic Drug Monitoring
6%
Systematic Review
6%
PARP Inhibitor
6%
Subretinal Fluid
6%
Avibactam Plus Ceftazidime
6%
Meningitis
6%
Cerebrospinal Fluid
6%
Diabetic Retinopathy
6%
Solid Organ Transplantation
6%
β-Lactamase inhibitor
6%
Beta Lactamase Inhibitor
6%
Eplerenone
6%
Thrombocytosis
6%
